DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02611232

UnknownPhase 2

Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults

Lead sponsor

University of Oulu

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

3

Recruiting sites

—

Enrollment

42

estimated

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•FPIR

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02611232
Org study IDLiraAAB18-30
Secondary ID2014-003667-37
Secondary ID3-SRA-2014-301-M-RJuvenile Diabetes Research Foundation International
Secondary IDU1111-1176-6062WHO

Timeline

Milestones

Study first posted2015-11-20estimated
Last update posted2022-01-25actual
Study start2015-12actual (month precision)
Primary completion2024-06estimated (month precision)
Study completion2024-06estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age30 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•18-30 years of age
•positive for at least 2 biochemical islet autoantibodies
•have normal glucose tolerance in OGTT
•are not pregnant

Exclusion criteria

•allergic to liraglutide or other ingredients of Victoza®
•Type 1 diabetes
•diabetic ketoacidosis
•previous treatment in the last three months with any antidiabetic medication
•impaired liver or kidney function or on dialysis
•severe heart failure
•severe stomach or gut problem resulting in gastroparesis, or inflammatory bowel disease
•past or current history of pancreatitis
•serum calcitonin value above normal (>50 ng/l or ≥3.4pmol/l)
•presence of any chronic metabolic, hematologic or malignant disease
•obesity BMI ≥30
•pregnant females and females of childbearing potential who are not using adequate contraceptive methods.
•breast-feeding

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Safety / tolerability / PK
2

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

FPIR (first phase insulin response)

Time frame:From baseline to 26 and 104 weeks

change from baseline, improvement

Secondary/protocol endpoint

Serum C-peptide AUC

Time frame:From baseline to 26 and 104 weeks

C-peptide AUC

concentration, improvement

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint/low confidence

Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia

Time frame:From baseline to 26 and 104 weeks

descriptive

componentsPancreatitis, Thyroid event, Documented hypoglycemia

Secondary/protocol endpoint

Tolerability

Time frame:From baseline to 26 and 104 weeks

Treatment-emergent AEs (any)

event count, event

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.